NYXH Stock Overview
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
Price History & Performance
|Historical stock prices|
|Current Share Price||€13.70|
|52 Week High||€30.00|
|52 Week Low||€13.32|
|1 Month Change||-17.77%|
|3 Month Change||-22.86%|
|1 Year Change||-27.21%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-29.74%|
Recent News & Updates
|NYXH||BE Medical Equipment||BE Market|
Return vs Industry: NYXH underperformed the Belgian Medical Equipment industry which returned -11.1% over the past year.
Return vs Market: NYXH underperformed the Belgian Market which returned -1.4% over the past year.
|NYXH Average Weekly Movement||6.7%|
|Medical Equipment Industry Average Movement||7.4%|
|Market Average Movement||5.2%|
|10% most volatile stocks in BE Market||7.9%|
|10% least volatile stocks in BE Market||3.1%|
Stable Share Price: NYXH is more volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NYXH's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Belgian stocks.
About the Company
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah Fundamentals Summary
|NYXH fundamental statistics|
Is NYXH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NYXH income statement (TTM)|
|Cost of Revenue||€6.36m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 09, 2022
|Earnings per share (EPS)||-1.11|
|Net Profit Margin||-2,159.08%|
How did NYXH perform over the long term?See historical performance and comparison
Is Nyxoah undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NYXH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NYXH's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: NYXH is unprofitable, so we can't compare its PE Ratio to the European Medical Equipment industry average.
PE vs Market: NYXH is unprofitable, so we can't compare its PE Ratio to the Belgian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NYXH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NYXH is good value based on its PB Ratio (2.5x) compared to the XE Medical Equipment industry average (3.3x).
How is Nyxoah forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NYXH's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if NYXH's earnings are forecast to grow faster than the Belgian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NYXH's revenue (69.1% per year) is forecast to grow faster than the Belgian market (0.8% per year).
High Growth Revenue: NYXH's revenue (69.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NYXH's Return on Equity is forecast to be high in 3 years time
How has Nyxoah performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NYXH is currently unprofitable.
Growing Profit Margin: NYXH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NYXH is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.
Accelerating Growth: Unable to compare NYXH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NYXH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.7%).
Return on Equity
High ROE: NYXH has a negative Return on Equity (-20.09%), as it is currently unprofitable.
How is Nyxoah's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NYXH's short term assets (€131.6M) exceed its short term liabilities (€12.6M).
Long Term Liabilities: NYXH's short term assets (€131.6M) exceed its long term liabilities (€10.7M).
Debt to Equity History and Analysis
Debt Level: NYXH has more cash than its total debt.
Reducing Debt: Insufficient data to determine if NYXH's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NYXH has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NYXH has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 37.4% each year.
What is Nyxoah current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NYXH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NYXH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NYXH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NYXH's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NYXH has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Olivier Taelman (49 yo)
Mr. Olivier Taelman serves as a Vice President of Sales Europe at Autonomic Technologies, Inc. Mr. Olivier Taelman is the Chief Executive Officer at Nyxoah S.A. since November 2019 and serves as its Execut...
CEO Compensation Analysis
Compensation vs Market: Olivier's total compensation ($USD773.46K) is about average for companies of similar size in the Belgian market ($USD732.19K).
Compensation vs Earnings: Olivier's compensation has increased whilst the company is unprofitable.
Experienced Management: NYXH's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: NYXH's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.7%.
Nyxoah S.A.'s employee growth, exchange listings and data sources
- Name: Nyxoah S.A.
- Ticker: NYXH
- Exchange: ENXTBR
- Founded: 2009
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €353.424m
- Shares outstanding: 25.80m
- Website: https://www.nyxoah.com
Number of Employees
- Nyxoah S.A.
- Rue Edouard Belin 12
- Walloon Brabant
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/19 00:00|
|End of Day Share Price||2022/05/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.